Compare Gogoro Inc (GGR) vs 10X Genomics Inc (TXG) Price & Performance

Gogoro (GGR) trades at $3.15, up 5.35% today, but faces bearish technical signals and weak profitability, with a net loss of $79.97M in 2025. Revenue grew modestly to $281.48M, yet margins remain negative. Recent news highlights board changes and a $61.8M equity investment, signaling internal restructuring efforts. The stock shows oversold conditions with an RSI of 27.68, but moving averages indicate a downtrend.

The outlook is cautious due to persistent losses and high debt-to-asset ratio of 60%, though low valuation ratios (P/S 0.16, P/B 0.5) may attract value investors. Risks include execution challenges and competitive pressures. Analysts are neutral with 100% hold ratings, reflecting uncertainty about near-term turnaround.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.